A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy

NCT02400866 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

58

Enrollment

NETWORK

Sponsor class

Conditions

Cancer

Interventions

DRUG: Olanzapine

Sponsor

Korean South West Oncology Group